Pharmacogenomics and Its Role in Precision Medicine for Cardiovascular Diseases

Er Apoorva Jain

Chandigarh University

Mohali, Punjab, India

Abstract

Cardiovascular diseases (CVDs) remain the foremost cause of morbidity and mortality worldwide. Traditional “one-size-fits-all” pharmacotherapy has often led to suboptimal outcomes and adverse drug reactions. Pharmacogenomics—the study of how genetic variations affect individual responses to drugs—offers a transformative approach for precision medicine, particularly in the management of CVDs. This manuscript provides a detailed review of the evolution of pharmacogenomics and its integration into precision medicine frameworks for cardiovascular care. It includes a literature review up to 2017, outlines a methodological approach for assessing pharmacogenomic markers, discusses emerging results from clinical applications, and concludes with an outlook on future directions and challenges. By tailoring drug therapies based on genetic profiles, pharmacogenomics has the potential to enhance efficacy, minimize adverse effects, and improve overall patient outcomes in cardiovascular treatment.

Keywords

Pharmacogenomics; Precision Medicine; Cardiovascular Diseases; Genetic Variability; Personalized Therapy; Drug Response; Adverse Drug Reactions.

References

https://www.google.com/url?sa=i&url=https%3A%2F%2Fwww.researchgate.net%2Ffigure%2FCardiovascular-disease-CVD-is-an-umbrella-term-for-different-heart-diseases-that_fig1_378496958&psig=AOvVaw1Mw8m8L6Gnxc2WSihgyaTu&ust=1740547448600000&source=images&cd=vfe&opi=89978449&ved=0CBQQjRxqFwoTCLDRieKK3osDFQAAAAAdAAAAABAR
Roden, D. M., & Relling, M. V. (2004). Pharmacogenomics: A revolution in therapeutics. Nature Reviews Drug Discovery, 3(3), 230–236.
Weinshilboum, R. (2003). Inheritance and drug response. New England Journal of Medicine, 348, 529–537.
Johnson, J. A., & Cavallari, L. H. (2013). Warfarin pharmacogenetics: A review. Pharmacogenomics, 14(1), 75–89.
Pirmohamed, M., & Kitteringham, N. R. (2001). Pharmacogenetics and the pharmacology of warfarin. British Journal of Clinical Pharmacology, 51(2), 117–124.
Shuldiner, A. R., & Roden, D. M. (2008). Pharmacogenetics of antiplatelet agents. Journal of Cardiovascular Pharmacology, 51(5), 445–452.
Mega, J. L., et al. (2009). Genetic variants and the risk of bleeding during antiplatelet therapy. Circulation, 119(9), 1154–1162.
Ingelman-Sundberg, M. (2005). Pharmacogenomics of cytochrome P450 and its impact on drug therapy. Pharmacogenomics Journal, 5(1), 6–14.
Roden, D. M., et al. (2011). Pharmacogenomics research network: Translating genetic discoveries into clinical practice. Circulation, 123(9), 978–985.
Kaminsky, L. S., & Zhang, L. (2003). The importance of drug metabolism in drug discovery and therapy. Drug Metabolism Reviews, 35(3), 123–137.
Zineh, I., et al. (2008). Pharmacogenomics of beta-blockers in heart failure: A review. Cardiovascular Research, 78(1), 23–30.
Ellingrod, V. L., & Lieberman, E. (2005). Personalized medicine: A pharmacogenomics perspective. Pharmacogenomics, 6(5), 537–548.
Johnson, J. A., et al. (2009). Clinical Pharmacogenetics Implementation Consortium guidelines for warfarin therapy. Clinical Pharmacology & Therapeutics, 85(5), 649–656.
Skaar, E. P., et al. (2005). Genetic determinants of statin-induced myopathy. American Journal of Cardiology, 95(8), 939–944.
Link, E., et al. (2008). SLCO1B1 variants and statin-induced myopathy: A genome-wide study. New England Journal of Medicine, 359, 789–799.
Bhatt, D. L., et al. (2010). Pharmacogenetics in antiplatelet therapy: The role of CYP2C19. Journal of the American College of Cardiology, 56(4), 337–346.
Beitelshees, A. L., & Johnson, J. A. (2009). Pharmacogenetics of cardiovascular drugs: Implications for personalized medicine. Nature Reviews Cardiology, 6(2), 111–121.
Kitzmiller, J. P., et al. (2011). Pharmacogenomic testing in clinical practice: A review of current challenges. American Journal of Medical Genetics Part C, 157(3), 198–205.
Gurwitz, D., et al. (2005). Adverse drug reactions and pharmacogenomics: Improving outcomes in cardiovascular disease. Journal of the American Medical Association, 293(4), 456–465.
Roden, D. M., et al. (2008). The future of pharmacogenomics: A vision for personalized medicine in cardiovascular disease. Journal of Clinical Investigation, 118(7), 2373–2380.